Rebastinib
Product Specifications
CAS Number
1020172-07-9
Target
Apoptosis, FLT, Bcr-Abl, Src
Related Pathways
Apoptosis, Angiogenesis, Tyrosine Kinase/Adaptors, Cytoskeletal Signaling
Purity
0.9984
Bioactivity
DCC-2036 (Rebastinib (DCC-2036) ) is a conformational control Bcr-Abl inhibitor for Abl1 (WT, IC50: 0.8 nM) and Abl1 (T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
Smiles
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1
Molecular Formula
C30H28FN7O3
Molecular Weight
553.59
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
245604 50 µL
EFHD1 (EF-hand Domain Family, Member D1, DKFZp781H0842, FLJ13612, MST133, MSTP133, PP3051)
Sign In for Pricing
View Details 
Q0500-01E-PE 200 µL
QKI, NT (Protein Quaking, HqkI, Hqk, HKQ) (PE) discontinued
Sign In for Pricing
View Details